# Phase I Study of PH100 (Ecklonia Cava Phlorotannins)

> **NCT04335045** · PHASE1 · COMPLETED · sponsor: **Phloronol Inc.** · enrollment: 48 (actual)

## Conditions studied

- Safety Issues

## Interventions

- **DRUG:** Placebo
- **DRUG:** PH100 100mg
- **DRUG:** PH100 200mg
- **DRUG:** PH100 400mg
- **DRUG:** PH100 800mg
- **DRUG:** PH100 1200mg
- **DRUG:** PH100 1600mg

## Key facts

- **NCT ID:** NCT04335045
- **Lead sponsor:** Phloronol Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-25
- **Primary completion:** 2014-12-08
- **Final completion:** 2014-12-08
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2020-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04335045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04335045, "Phase I Study of PH100 (Ecklonia Cava Phlorotannins)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04335045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*